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Conclusions: Calibration of diodes for in vivo dosimetry in 
breast treatments delivered using a sliding window IMRT 
technique requires non-linear CFs. Setting the calibration 
geometry close to the average irradiation geometry 
minimizes the value and uncertainty of CFs. We recommend 
two or more detectors per field, placed on high-fluence 
regions, to avoid false-positive warnings due to variations of 
MLC transmission. 
This work was funded by a grant from the Barcelona Board of 
the Spanish Association Against Cancer (AECC) 2012. 
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Purpose/Objective: In our institution, almost all external 
beam radiotherapy treatments are verified using in vivo 
portal dosimetry, for reasons of efficiency and patient safety. 
Deviations between planned and EPID reconstructed dose 
occur mainly due to three causes: dose reconstruction model 
limitations, patient related causes and external factors. The 
aims of this work are: 1) to quantify the alert rate per 
treatment site, 2) to classify alerts according to the three 
abovementioned causes and 3) to prioritize improvement of 
our method. 
Materials and Methods: Portal images are converted to a 3D 
patient dose distribution by means of a simple back-
projection model and the planning CT, and compared to the 
planned dose distribution by means of 3D gamma evaluation 
(default 3%, 3mm). Criteria are based on mean γ (γmean), 1% 
maximum γ (γ1%), percentage γ<1 (Pγ<1) and dose difference 
at the dose reconstruction point (DRP) (ΔDDRP). For 
IMRT/VMAT 3 different criteria levels are applied: (a) 
default: γmean < 0.5, γ1% < 2, Pγ<1 > 85%, ΔDDRP < 3%, (b) breast: 
γmean < 1.4, γ1% < 5, Pγ<1 > 50%, ΔDDRP < 3%, (c) GE and H&N: 
γmean < 0.7, γ1% < 2.5, Pγ<1 > 80%, ΔDDRP < 4%. Non-IMRT 
treatments (mostly palliative) use (9%, 3mm) gamma 
parameters and γmean < 0.9, ΔDDRP < 10% as alert criteria. The 
causes of deviation of all alerts from 2013 have been 
indicated by an experienced medial physicist. Alerts that 
resulted in clinical intervention were excluded (18 cases). 
The classification was done using information in the R&V 
system, anatomical information from CBCT, and the original 
comments when the alert was first reviewed clinically. 
Results: Table 1 shows the number of alerts per treatment 
site and assigned sources of deviation. 1397 out of 5766 
verified plans were alerted (24%). Model limitations, patient 
related causes and external sources gave rise to false positive 
alerts in 1107 (19%), 557 (10%) and 101 cases (2%), 
respectively. In spite of less strict criteria, the alert rate in 
breast treatments is still 33%. This treatment site suffers 
from the absence of missing tissue compensation in our 
model and a well-known problem with transit dosimetry: 
setup errors (offline setup protocol). In addition, the use of 
bolus material in treatment planning is incompatible with 
portal dosimetry, contributing considerably to the alert rate. 
In all treatments, an unfavorable choice of the dose 
reference point location (e.g., on a high dose gradient) is an 
important cause of alerts. The impact of anatomy changes on 
portal dosimetry results is a topic of current research. 
Conclusions: 76% of in vivo portal dosimetry results is within 
criteria. Limitations of the back-projection model are the 
main source of alerts. In 10% of plans an alert is caused by 
patient setup and anatomy changes. This can be regarded as 
the baseline alert rate for in vivo portal dosimetry using the 
current criteria. Efforts to decrease the alert rate should 
focus on breast treatments, handling inhomogeneities and 
choice of dose reconstruction point. 
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Purpose/Objective: Kilovoltage x-ray radiotherapy units play 
an important role in skin cancer treatment. Over the last ten 
years, our QA programme has shown a decrease in dose rate 
in our Therapax SXT 150 (Pantak Seifert) unit. We studied 
whether tube metallization could explain this variation in 
dose rate by comparing our QA records with simulated data. 
Materials and Methods: The Therapax SXT 150 has a metal-
ceramic x-ray tube (MXR-161) and provides 8 beam qualities 
ranging from 50kV, 0.45 mm Al HVL (lowest beam quality) to 
150 kV, 1.48 mm Cu HVL. A set of applicators defines circular 
field sizes with diameters ranging from 1 to 15 cm. The QA 
programme for this unit, based on IAEA TECDOC-1151 (and 
TRS-398 for absorbed dose Dw determination), quarterly 
assesses the constancy of: Dw rate, HVL, quality index QI 
(defined as the ratio of absorbed doses at two fixed depths), 
output factors, field size, symmetry, homogeneity, timer 
